Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history.
"We've followed the work Fred Hutch scientists have been conducting over the last few years in the promising area of immunotherapy to combat cancer and are so encouraged by the spectacular results in patients with leukemia and lymphoma," said Mike Bezos on behalf of the Bezos family. "The potential to now attack other cancers with this approach is too huge not to take this research to the next level. We believe the scientists at Fred Hutch are ready to take this challenge, and we are pleased to be supporting their efforts."
Larry Corey, M.D., president and director of the Hutch, said "We are immensely grateful to the Bezos family for this remarkable gift. It will allow us to extend the momentum we have established in using genetically modified human T cells to treat cancer."
The gift will enable Fred Hutch, along with its partners at the University of Washington and Seattle Cancer Care Alliance, to combine its long record of discovery in cancer immunotherapy with the latest technologies to transform treatment for common solid-tumor cancers, including those of the lung, ovaries, pancreas and colon.
"The contribution comes at a pivotal time," said Corey. "We have strong indications that immunotherapy will be effective for a much broader range of cancers, and we now have resources to utilize our technologies to discover targets for some of the most deadly cancers."
Frederick R. Appelbaum, M.D., executive vice president and deputy director of Fred Hutch, called the Bezos family's gift "absolutely invaluable."
"Their enthusiasm for this work and the impact it can have on patients means a great deal to us. They are extraordinary allies," he said.
This is not the first time the Bezos family has partnered with Fred Hutch to fuel lifesaving cancer research. In 2009, the family made a catalytic $10 million challenge gift to support immunotherapy research. With the collective philanthropic support generated by that challenge, Fred Hutch researchers have steadily advanced their work from laboratory experiments to early phase trials for patients with certain leukemias and lymphomas.
"We've developed methods for significantly improving adoptive T-cell therapy, in which certain immune cells are reprogrammed to recognize and destroy a patient's cancer," Appelbaum said. "Early results with lymphoma and leukemia patients who were resistant to chemotherapy have been incredibly encouraging. These are patients with literally pounds of tumor that are treated with less than a thimbleful of T cells, and their tumors melt away. They get complete remissions in a matter of days - not months, days."
Now, with the Bezos family's continued partnership, Seattle-based scientists can supercharge an even broader array of projects and extend these research successes beyond blood cancers to the so-called "solid tumors."
"Seeing our initial investment translated into a therapy that is truly changing patients' lives in a profound way is so motivating. It gives us great optimism for the future," Jackie Bezos said.
"Cancer got the jump on us, but it doesn't have to have the last word."